Conference
Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia
Abstract
Abstract
It is estimated that 4-10% of patients with chronic lymphocytic leukemia (CLL) will develop autoimmune hemolytic anemia (AIHA) over the course of their disease. Ibrutinib has proven to be effective in treatment of relapsed, refractory, 17p deleted, and treatment naïve CLL. The effect of ibrutinib on AIHA in the context of CLL has not been established since patients with active hemolysis were excluded from major …
Authors
Garcia-Horton A; St. Bernard R; Lazo-Langner A; Xenocostas A; Mangel J; Howson-Jan K; Lam S; Hsia CC
Volume
132
Publisher
American Society of Hematology
Publication Date
November 29, 2018
DOI
10.1182/blood-2018-99-120129
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971